...
首页> 外文期刊>Journal of diabetes and its complications >Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation
【24h】

Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation

机译:联合疗法可改善2型糖尿病的长期大血管和微血管预后:早期启动的依据和证据

获取原文
获取原文并翻译 | 示例

摘要

Diabetes is a leading cause of macrovascular and microvascular complications that can increase the risk of mortality if not properly managed. Proper glucose control can reduce the incidence of these complications, in particular those of the microvasculature. Over the last similar to 10 years, the cardiovascular safety of glucose-lowering drugs has come to the forefront of diabetes management and clinical trial design. While early combination therapy improves glycemic control, its impact on long-term outcomes, is not as clearly understood. The objective of this review is to examine the evidence of early combination therapy for the treatment of type 2 diabetes mellitus as it relates to studies of long-term microvascular and macrovascular outcomes. (C) 2016 The Author. Published by Elsevier Inc.
机译:糖尿病是大血管和微血管并发症的主要原因,如果管理不当,会增加死亡的风险。适当的葡萄糖控制可以减少这些并发症的发生率,特别是微脉管系统并发症的发生率。在过去的大约10年中,降糖药物的心血管安全性已成为糖尿病管理和临床试验设计的最前沿。尽管早期的联合疗法可以改善血糖控制,但对长期结果的影响尚不清楚。这篇综述的目的是检查早期联合疗法治疗2型糖尿病的证据,因为它与长期微血管和大血管结局的研究有关。 (C)2016作者。由Elsevier Inc.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号